Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir : a case series

• Published in: AIDS (London) Vol. 20; no. 5; pp. 791 - 793
• Main Authors: GARVEY, Lucy, THOMSON, Emma C, TAYLOR, Graham P
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 21.03.2006
• Subjects: Adolescent; Adult; Anti-HIV Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Biological and medical sciences; Brain - pathology; Cytosine - analogs & derivatives; Cytosine - therapeutic use; Female; HIV Protease Inhibitors - therapeutic use; Human viral diseases; Humans; Infectious diseases; Leukoencephalopathy, Progressive Multifocal - diagnosis; Leukoencephalopathy, Progressive Multifocal - drug therapy; Leukoencephalopathy, Progressive Multifocal - mortality; Magnetic Resonance Imaging; Male; Medical sciences; Organophosphonates - therapeutic use; Pharmacology. Drug treatments; Survival Rate; Viral diseases; Viral diseases of the nervous system; Human; Nervous system diseases; Acyclic nucleotide; Prognosis; Organic phosphonate; Cidofovir; Survival; Cerebral disorder; Inflammatory disease; Progressive multifocal leukoencephalopathy; Infection; Virus; Viral disease; Central nervous system disease; Antiviral; Pyrimidine nucleotide; Protease inhibitor; Slow virus
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/01.aids.0000216390.83351.87

The prognosis of patients with progressive multifocal leukoencephalopathy (PML) has been reported to be poor even in the HAART era, with median survivals of 131-646 days in previous studies. We report a much longer median survival in all patients with confirmed PML presenting to our unit between 1998 and 2005.